Early De-Risking: In Vitro Safety Strategies for Pre-IND Success
Safety data is no longer just a regulatory checkbox - it’s a strategic advantage. Discover how in vitro and computational tools reduce the reliance on animal testing and support smarter, earlier decision-making in drug discovery.
Beyond templates: advancing protein–protein interaction structure prediction with AI
By Dr Alan Nafiiev (CEO and Founder of Receptor.AI)
Fighting MS progression: why GPR17 is the target to watch
By Anja Harmeier (CEO of Rewind Therapeutics)
Fast-tracking advanced therapies without compromising regulatory success
By Drug Target Review
Mass spectrometry workflows powering the future of biologics
By Drug Target Review
Beyond the Lab: Biomarkers Powering Tomorrow’s Therapies
Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.
Beyond the Lab: Clinical Trials
Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.
From data to therapy: emerging tech driving cancer drug discovery
By Dr Malini Rajagopalan (Vice President and Head of Marketing…